The FDA will provide faster regulatory review of generic drugs that are tested in and manufactured in the U.S. using domestically sourced active pharmaceutical ingredients. This FDA pilot program is part of a broader Trump administration strategy to reshore pharmaceutical production.
The post FDA Pilot Program Creates New Path for Faster Regulatory Review of Generic Drugs appeared first on MedCity News.
